Brevan Howard Capital Management LP Has $5.48 Million Holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Brevan Howard Capital Management LP increased its holdings in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) by 141.5% in the 4th quarter, according to its most recent filing with the SEC. The fund owned 7,690 shares of the biopharmaceutical company's stock after purchasing an additional 4,506 shares during the period. Brevan Howard Capital Management LP's holdings in Regeneron Pharmaceuticals were worth $5,478,000 at the end of the most recent reporting period.

Other hedge funds have also recently added to or reduced their stakes in the company. Willner & Heller LLC lifted its stake in Regeneron Pharmaceuticals by 3.9% in the 4th quarter. Willner & Heller LLC now owns 399 shares of the biopharmaceutical company's stock valued at $284,000 after purchasing an additional 15 shares during the last quarter. OLD Second National Bank of Aurora lifted its position in shares of Regeneron Pharmaceuticals by 0.5% in the fourth quarter. OLD Second National Bank of Aurora now owns 2,843 shares of the biopharmaceutical company's stock valued at $2,025,000 after buying an additional 15 shares during the last quarter. Rakuten Securities Inc. boosted its stake in shares of Regeneron Pharmaceuticals by 62.5% during the 4th quarter. Rakuten Securities Inc. now owns 39 shares of the biopharmaceutical company's stock worth $28,000 after acquiring an additional 15 shares during the period. TD Private Client Wealth LLC raised its stake in Regeneron Pharmaceuticals by 9.6% in the 4th quarter. TD Private Client Wealth LLC now owns 171 shares of the biopharmaceutical company's stock valued at $122,000 after acquiring an additional 15 shares during the period. Finally, Manchester Capital Management LLC raised its stake in Regeneron Pharmaceuticals by 12.6% in the 4th quarter. Manchester Capital Management LLC now owns 161 shares of the biopharmaceutical company's stock valued at $115,000 after acquiring an additional 18 shares during the period. Institutional investors own 83.31% of the company's stock.

Analyst Ratings Changes

Several brokerages have recently weighed in on REGN. Piper Sandler dropped their price objective on shares of Regeneron Pharmaceuticals from $1,195.00 to $1,013.00 and set an "overweight" rating on the stock in a research report on Monday, January 27th. Guggenheim dropped their price target on Regeneron Pharmaceuticals from $940.00 to $810.00 and set a "buy" rating for the company in a report on Thursday, May 1st. Leerink Partners upgraded shares of Regeneron Pharmaceuticals from a "market perform" rating to an "outperform" rating and lifted their price objective for the stock from $762.00 to $834.00 in a research note on Wednesday, February 5th. Royal Bank of Canada decreased their target price on shares of Regeneron Pharmaceuticals from $1,051.00 to $943.00 and set an "outperform" rating on the stock in a research report on Wednesday, April 30th. Finally, Bernstein Bank dropped their price target on shares of Regeneron Pharmaceuticals from $1,070.00 to $1,000.00 in a research report on Tuesday, February 4th. One investment analyst has rated the stock with a sell rating, five have assigned a hold rating, eighteen have assigned a buy rating and three have given a strong buy rating to the company's stock. According to MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and a consensus price target of $892.60.

Regeneron Pharmaceuticals Trading Down 3.6 %

Shares of NASDAQ:REGN traded down $19.89 during midday trading on Friday, hitting $527.78. 1,498,740 shares of the stock were exchanged, compared to its average volume of 766,358. The business's 50-day moving average price is $616.03 and its 200 day moving average price is $699.76. The stock has a market capitalization of $57.70 billion, a price-to-earnings ratio of 13.79, a P/E/G ratio of 2.34 and a beta of 0.43. Regeneron Pharmaceuticals, Inc. has a 12 month low of $520.50 and a 12 month high of $1,211.20. The company has a debt-to-equity ratio of 0.09, a quick ratio of 3.95 and a current ratio of 4.73.

Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) last posted its quarterly earnings data on Tuesday, April 29th. The biopharmaceutical company reported $8.22 earnings per share for the quarter, missing analysts' consensus estimates of $8.83 by ($0.61). Regeneron Pharmaceuticals had a net margin of 31.07% and a return on equity of 16.32%. The company had revenue of $3.03 billion during the quarter, compared to analyst estimates of $3.40 billion. During the same quarter in the previous year, the company earned $9.55 earnings per share. The business's revenue for the quarter was down 3.7% on a year-over-year basis. Analysts predict that Regeneron Pharmaceuticals, Inc. will post 35.92 earnings per share for the current year.

Regeneron Pharmaceuticals Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Friday, June 6th. Stockholders of record on Tuesday, May 20th will be given a dividend of $0.88 per share. This represents a $3.52 annualized dividend and a dividend yield of 0.67%. The ex-dividend date is Tuesday, May 20th. Regeneron Pharmaceuticals's dividend payout ratio (DPR) is presently 8.96%.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.